

FOR IMMEDIATE RELEASE

Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GENEGO ENTERS LICENSING AGREEMENT WITH INVITROGEN CORPORATION

St. Joseph, MI – June 1, 2004 – GeneGo, Inc., a company with a proprietary computational platform for Systems Biology that combines analytical tools, data content and algorithms for understanding complex interconnected pathways that are affected in common human diseases, today announced that it has entered into a multi-year licensing agreement with Invitrogen Corp. (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery. Under the agreement, the companies plan to work closely together to develop new capabilities. Further details and financial arrangements were not disclosed at this time, but will be divulged in greater detail as milestones of the collaboration are achieved.

“We are delighted to work with Invitrogen towards our shared goal of providing life science researchers with the tools they need to produce meaningful answers from their experiments,” said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo.

“We are impressed with the quality and usability of biological pathways from GeneGo. Licensing of these pathways will help us in making bioinformatics an intrinsic part of Invitrogen’s solutions set for life science research,” said Michael Stapleton, Ph.D., General Manager and Vice President of Invitrogen’s bioinformatics business.

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo’s first product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. MetaCore™ integrates all levels of cellular functionality -from membrane receptors to signal transduction, transcription factors, and effector networks and is based on the proprietary database of curated functional pathways and networks. For more information, please visit the company's Web site at www.genego.com.

MetaCore™ and MetaDrug™ are trademarks of GeneGo, Inc.

About Invitrogen

Invitrogen Corp. (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology --placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen has headquarters in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 3,000 scientists and other professionals. For more information about Invitrogen, visit the company's Web site at www.invitrogen.com.